Immunotherapy before surgery for localized cancers
Part of Cancer clinical trials.
This trial tests immunotherapy before surgery for people with localized solid tumors. It aims to improve how well the cancer is controlled and may help shrink tumors so they can be removed more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 40 kg (about 88 lbs).
- You have a solid tumor that has not spread to other parts of the body (localized) and you are scheduled to receive treatment before surgery to shrink it.
- You are willing to have blood draws and tumor biopsies for research purposes.
- You have adequate organ function (kidney, liver, blood cells) as determined by lab tests.
- You do not have a history of severe autoimmune disease or active serious infections.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can improve outcomes for patients with stage III melanoma that can be removed. It is for people who have not had certain treatments recently or whose melanoma is not in the eye.
This trial tests different immunotherapy treatments for people with advanced cancer that has spread or cannot be removed by surgery. It aims to find out which treatments work best by studying your tumor and blood samples over time.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
Hear when a new Localized Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.